E Randall Lanier

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi request reprint Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type
    Richard Hazen
    Department of Virology, GlaxoSmithKline, Research Triange Park, North Carolina 27709, USA
    J Acquir Immune Defic Syndr 32:255-8. 2003
  2. ncbi request reprint Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors
    E Randall Lanier
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Antivir Ther 9:37-45. 2004
  3. ncbi request reprint Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens
    E R Lanier
    GlaxoSmithKline, Research Triangle Park, NC, USA
    HIV Med 5:394-9. 2004
  4. ncbi request reprint Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1
    E Randall Lanier
    GlaxoSmithKline, Research Triangle Park, NC 27705, USA
    J Acquir Immune Defic Syndr 39:519-22. 2005
  5. doi request reprint Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1
    Mark R Underwood
    GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Infect Dis 199:84-8. 2009
  6. ncbi request reprint Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview
    John A Bartlett
    AIDS Research and Treatment Center, Duke University Medical Center, Durham, NC, USA
    J Acquir Immune Defic Syndr 41:323-31. 2006
  7. pmc Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
    Jeffrey A Johnson
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Med 5:e158. 2008
  8. ncbi request reprint Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy
    Jesus Saavedra-Lozano
    UT Southwestern Medical Center, Dallas, TX, USA
    Pediatr Infect Dis J 25:1142-52. 2006
  9. ncbi request reprint Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy
    Diana Averbuch
    Hadassah University Medical Center, Jerusalem, Israel
    Pediatr Infect Dis J 25:1049-56. 2006
  10. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type
    Richard Hazen
    Department of Virology, GlaxoSmithKline, Research Triange Park, North Carolina 27709, USA
    J Acquir Immune Defic Syndr 32:255-8. 2003
    ....
  2. ncbi request reprint Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors
    E Randall Lanier
    GlaxoSmithKline, Research Triangle Park, NC, USA
    Antivir Ther 9:37-45. 2004
    ..To evaluate HIV-1 reverse transcriptase genotypic and phenotypic indicators of resistance to abacavir (ABC) as predictors of ABC antiviral efficacy...
  3. ncbi request reprint Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens
    E R Lanier
    GlaxoSmithKline, Research Triangle Park, NC, USA
    HIV Med 5:394-9. 2004
    ....
  4. ncbi request reprint Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1
    E Randall Lanier
    GlaxoSmithKline, Research Triangle Park, NC 27705, USA
    J Acquir Immune Defic Syndr 39:519-22. 2005
    ..Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination...
  5. doi request reprint Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1
    Mark R Underwood
    GlaxoSmithKline, Inc, Research Triangle Park, North Carolina 27709 3398, USA
    J Infect Dis 199:84-8. 2009
    ..These findings underscore the limitations of stand-alone phenotypic susceptibility measures and emphasize the importance of complementary and/or more sensitive techniques...
  6. ncbi request reprint Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview
    John A Bartlett
    AIDS Research and Treatment Center, Duke University Medical Center, Durham, NC, USA
    J Acquir Immune Defic Syndr 41:323-31. 2006
    ..To identify optimal first-line therapies based on the rate of virologic success (VS) and the preservation of future treatment options in antiretroviral therapy (ART)-naive subjects...
  7. pmc Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy
    Jeffrey A Johnson
    Division of HIV AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS Med 5:e158. 2008
    ..We used sensitive and simple tests to investigate evidence of transmitted drug resistance in antiretroviral drug-naïve persons and assess the clinical implications of minority drug-resistant variants...
  8. ncbi request reprint Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy
    Jesus Saavedra-Lozano
    UT Southwestern Medical Center, Dallas, TX, USA
    Pediatr Infect Dis J 25:1142-52. 2006
    ..The present study evaluated the safety and virologic, immunologic and neuropsychological responses of an ARV regimen including high-dose ABC in children with HIV-AE...
  9. ncbi request reprint Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy
    Diana Averbuch
    Hadassah University Medical Center, Jerusalem, Israel
    Pediatr Infect Dis J 25:1049-56. 2006
    ..We retrospectively studied the effect of the lamivudine-induced reverse transcription mutation M184V on selection of thymidine analog mutations (TAMs) in HIV subtype C-infected children and on clinical outcome...
  10. ncbi request reprint Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
    ..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
  11. ncbi request reprint Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
    Martin Markowitz
    The Aaron Diamond AIDS Research Center, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 39:257-64. 2005
    ..The ESS40013 study tested 4-drug induction followed by 3-drug maintenance as initial antiretroviral therapy (ART) to reduce HIV RNA rapidly and then to simplify to an effective yet more convenient and tolerable regimen...
  12. ncbi request reprint Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
    Edwin DeJesus
    IDC Research, Altamonte Springs, FL 32701, USA
    Clin Infect Dis 39:1038-46. 2004
    ..Evaluating other unique nucleoside reverse-transcriptase inhibitor (NRTI) combinations for long-term viral suppression is desirable...
  13. ncbi request reprint The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA
    David M Margolis
    Department of Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, USA
    J Acquir Immune Defic Syndr 31:45-9. 2002
    ..The possibility that MMF may enhance the effect of selected NRTIs and be tolerated in late stage HIV disease deserves careful randomized study...
  14. ncbi request reprint Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy
    Cynthia McCoig
    Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75390 9063, USA
    J Pediatr 141:36-44. 2002
    ..This study evaluated the effect of treatment with abacavir/lamivudine/zidovudine versus lamivudine/zidovudine on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV) RNA and clinical manifestations of HIV encephalopathy in children...
  15. ncbi request reprint Cerebrospinal fluid and plasma concentrations of proinflammatory mediators in human immunodeficiency virus-infected children
    Cynthia McCoig
    Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA
    Pediatr Infect Dis J 23:114-8. 2004
    ..Studies suggest that HIV replication and the release of proinflammatory mediators in the central nervous system contribute to the pathogenesis of HIV dementia in adults...